376 related articles for article (PubMed ID: 30723263)
21. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS
J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854
[TBL] [Abstract][Full Text] [Related]
22. Lead Optimization Studies Towards Finding NS2B/NS3 Protease Targetspecific Inhibitors as Potential Anti-dengue Drug-like Compounds.
Gurusamy M; Abdul JF
Curr Drug Discov Technol; 2019; 16(3):307-314. PubMed ID: 29984660
[TBL] [Abstract][Full Text] [Related]
23. Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence.
Piccirillo E; Merget B; Sotriffer CA; do Amaral AT
J Comput Aided Mol Des; 2016 Mar; 30(3):251-70. PubMed ID: 26923377
[TBL] [Abstract][Full Text] [Related]
24. Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: structure-based virtual screening, molecular docking and molecular dynamics simulation studies.
Purohit P; Sahoo S; Panda M; Sahoo PS; Meher BR
J Mol Model; 2022 Oct; 28(11):365. PubMed ID: 36274116
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.
Vincetti P; Caporuscio F; Kaptein S; Gioiello A; Mancino V; Suzuki Y; Yamamoto N; Crespan E; Lossani A; Maga G; Rastelli G; Castagnolo D; Neyts J; Leyssen P; Costantino G; Radi M
J Med Chem; 2015 Jun; 58(12):4964-75. PubMed ID: 26039671
[TBL] [Abstract][Full Text] [Related]
26. Rational discovery of dengue type 2 non-competitive inhibitors.
Heh CH; Othman R; Buckle MJ; Sharifuddin Y; Yusof R; Rahman NA
Chem Biol Drug Des; 2013 Jul; 82(1):1-11. PubMed ID: 23421589
[TBL] [Abstract][Full Text] [Related]
27. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.
Ahmad S; Waheed Y; Ismail S; Bhatti S; Abbasi SW; Muhammad K
Molecules; 2021 Mar; 26(5):. PubMed ID: 33800013
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease.
Bharadwaj S; Lee KE; Dwivedi VD; Yadava U; Panwar A; Lucas SJ; Pandey A; Kang SG
Sci Rep; 2019 Dec; 9(1):19059. PubMed ID: 31836806
[TBL] [Abstract][Full Text] [Related]
29. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.
Wichapong K; Pianwanit S; Sippl W; Kokpol S
J Mol Recognit; 2010; 23(3):283-300. PubMed ID: 19693793
[TBL] [Abstract][Full Text] [Related]
30. Zika virus NS2B/NS3 proteinase: A new target for an old drug - Suramin a lead compound for NS2B/NS3 proteinase inhibition.
Coronado MA; Eberle RJ; Bleffert N; Feuerstein S; Olivier DS; de Moraes FR; Willbold D; Arni RK
Antiviral Res; 2018 Dec; 160():118-125. PubMed ID: 30393012
[TBL] [Abstract][Full Text] [Related]
31. Identification and characterization of new potent inhibitors of dengue virus NS5 proteinase from Andrographis paniculata supercritical extracts on in animal cell culture and in silico approaches.
Kaushik S; Dar L; Kaushik S; Yadav JP
J Ethnopharmacol; 2021 Mar; 267():113541. PubMed ID: 33152438
[TBL] [Abstract][Full Text] [Related]
32. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
J Virol; 2017 May; 91(10):. PubMed ID: 28298600
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the inhibitory potency of anti-dengue phytocompounds against DENV-2 NS2B-NS3 protease: virtual screening, ADMET profiling and molecular dynamics simulation investigations.
Purohit P; Barik D; Agasti S; Panda M; Meher BR
J Biomol Struct Dyn; 2024 Apr; 42(6):2990-3009. PubMed ID: 37194462
[TBL] [Abstract][Full Text] [Related]
34. Ethyl 4-(4-methylphenyl)-4-pentenoate from Vetiveria zizanioides Inhibits Dengue NS2B-NS3 Protease and Prevents Viral Assembly: A Computational Molecular Dynamics and Docking Study.
Lavanya P; Ramaiah S; Anbarasu A
Cell Biochem Biophys; 2016 Sep; 74(3):337-51. PubMed ID: 27324039
[TBL] [Abstract][Full Text] [Related]
35. Serotype-specific interactions among functional domains of dengue virus 2 nonstructural proteins (NS) 5 and NS3 are crucial for viral RNA replication.
Teramoto T; Balasubramanian A; Choi KH; Padmanabhan R
J Biol Chem; 2017 Jun; 292(23):9465-9479. PubMed ID: 28396347
[TBL] [Abstract][Full Text] [Related]
36. Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes.
Dražić T; Kopf S; Corridan J; Leuthold MM; Bertoša B; Klein CD
J Med Chem; 2020 Jan; 63(1):140-156. PubMed ID: 31804823
[TBL] [Abstract][Full Text] [Related]
37. Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease.
Sarwar MW; Riaz A; Dilshad SMR; Al-Qahtani A; Nawaz-Ul-Rehman MS; Mubin M
BMC Struct Biol; 2018 Apr; 18(1):6. PubMed ID: 29673347
[TBL] [Abstract][Full Text] [Related]
38. Discovering key residues of dengue virus NS2b-NS3-protease: New binding sites for antiviral inhibitors design.
Aguilera-Pesantes D; Robayo LE; Méndez PE; Mollocana D; Marrero-Ponce Y; Torres FJ; Méndez MA
Biochem Biophys Res Commun; 2017 Oct; 492(4):631-642. PubMed ID: 28343993
[TBL] [Abstract][Full Text] [Related]
39. Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay.
Chu JJ; Lee RC; Ang MJ; Wang WL; Lim HA; Wee JL; Joy J; Hill J; Brian Chia CS
Antiviral Res; 2015 Jun; 118():68-74. PubMed ID: 25823617
[TBL] [Abstract][Full Text] [Related]
40. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
